CC
LRMR icon

Clearline Capital’s Larimar Therapeutics LRMR Stock Holding History

Clearline Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-31,227
Closed -$2.36M – 47
2015
Q4 		$2.36M Buy
+31,227
New +$5.02M 0.37% 42

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Clearline Capital's LRMR Position: Q1 2016 in Review

Clearline Capital sold out of Larimar Therapeutics (LRMR) in Q1 2016, closing a stake of 31,227 shares — an estimated $2.36M sold.

Clearline Capital first reported a position in LRMR in Q4 2015 and held it in 1 quarter. The position peaked at $2.36M in Q4 2015. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2016.

  • Clearline Capital reported no remaining Larimar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Clearline Capital sold 31,227 Larimar Therapeutics shares in Q1 2016, an estimated $2.36M.
  • Clearline Capital first reported a position in Larimar Therapeutics in Q4 2015 and held it in 1 quarter.
  • Clearline Capital's Larimar Therapeutics position peaked at $2.36M in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2016.

Based on Clearline Capital's 13F filing for Q1 2016, filed 16 May 2016.